- 2 years ago
6 August 2021 Gilead’s second CAR-T cell therapy TECARTUS (brexucabtagene autoleucel) has gained TGA approval…
This is subscriber-only content. Please login to continue reading.
6 August 2021 Gilead’s second CAR-T cell therapy TECARTUS (brexucabtagene autoleucel) has gained TGA approval…
This is subscriber-only content. Please login to continue reading.